CD19 and acute lymphoblastic leukemia: Investigators of the University of Pennsylvania (UPenn), after showing the efficacy of their CD19-BBz construct CTL019 – now developed as tisa-cel – in 2 children with R/R B-ALL achieving CR (20), reported on a single-center phase I/IIa study on 30 R/R B-ALL patients.